160 related articles for article (PubMed ID: 22697293)
1. High survivin expression as a risk factor in patients with anal carcinoma treated with concurrent chemoradiotherapy.
Fraunholz I; Rödel C; Distel L; Rave-Fränk M; Kohler D; Falk S; Rödel F
Radiat Oncol; 2012 Jun; 7():88. PubMed ID: 22697293
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor expression as prognostic marker in patients with anal carcinoma treated with concurrent chemoradiation therapy.
Fraunholz I; Rödel F; Kohler D; Diallo-Georgiopoulou M; Distel L; Falk S; Rödel C
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):901-7. PubMed ID: 23755922
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy.
Rödel F; Wieland U; Fraunholz I; Kitz J; Rave-Fränk M; Wolff HA; Weiss C; Wirtz R; Balermpas P; Fokas E; Rödel C
Int J Cancer; 2015 Jan; 136(2):278-88. PubMed ID: 24839133
[TBL] [Abstract][Full Text] [Related]
4. Polo-like kinase 3 and phosphoT273 caspase-8 are associated with improved local tumor control and survival in patients with anal carcinoma treated with concomitant chemoradiotherapy.
Rödel F; Martin D; Helmke C; Balermpas P; Fokas E; Wieland U; Rave-Fränk M; Kitz J; Matthess Y; Raab M; Strebhardt K; Rödel C
Oncotarget; 2016 Aug; 7(33):53339-53349. PubMed ID: 27462786
[TBL] [Abstract][Full Text] [Related]
5. Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811.
Doll CM; Moughan J; Klimowicz A; Ho CK; Kornaga EN; Lees-Miller SP; Ajani JA; Crane CH; Kachnic LA; Okawara GS; Berk LB; Roof KS; Becker MJ; Grisell DL; Ellis RJ; Sperduto PW; Marsa GW; Guha C; Magliocco AM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):554-562. PubMed ID: 28126304
[TBL] [Abstract][Full Text] [Related]
6. A population-based analysis of the impact of 1 vs. 2 doses of mitomycin on patterns of failure of anal cancer patients treated with concurrent chemoradiotherapy.
Joseph K; Al Habsi Z; Abraham A; Elangovan A; Ghosh S; Pham T; Shreekumar D; Ramji Z; Paulson K; Tankel K; Usmani N; Severin D; Schiller D; Wong C; Mulder K; Karachiwala H; Doll C; King K; Nijjar T
Radiother Oncol; 2024 Jul; 196():110219. PubMed ID: 38479443
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of chemoradiotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of the HIV disease.
Fraunholz IB; Haberl A; Klauke S; Gute P; Rödel CM
Dis Colon Rectum; 2014 Apr; 57(4):423-31. PubMed ID: 24608297
[TBL] [Abstract][Full Text] [Related]
8. Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles mitomycin-C.
White EC; Goldman K; Aleshin A; Lien WW; Rao AR
Radiother Oncol; 2015 Nov; 117(2):240-5. PubMed ID: 26347494
[TBL] [Abstract][Full Text] [Related]
9. Definitive Chemoradiotherapy for Anal Carcinoma: Long-Term Results Based on Consistent Time-to-Event Endpoints.
De Felice F; Martinetti MT; Orelli S; Bulzonetti N; Musio D; Tombolini V
Oncology; 2018; 94(1):25-30. PubMed ID: 28918425
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Relevance of HPV Infection and p16 Overexpression in Squamous Cell Anal Cancer.
Mai S; Welzel G; Ottstadt M; Lohr F; Severa S; Prigge ES; Wentzensen N; Trunk MJ; Wenz F; von Knebel-Doeberitz M; Reuschenbach M
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):819-27. PubMed ID: 26530750
[TBL] [Abstract][Full Text] [Related]
11. Node-negative T1-T2 anal cancer: radiotherapy alone or concomitant chemoradiotherapy?
Zilli T; Schick U; Ozsahin M; Gervaz P; Roth AD; Allal AS
Radiother Oncol; 2012 Jan; 102(1):62-7. PubMed ID: 21993403
[TBL] [Abstract][Full Text] [Related]
12. Pilot study of FMC (5-fluorouracil, mitomycin C, and cisplatin) with radiotherapy for patients with anal cancer.
Lee IH; Lee SJ; Kang BW; Chae YS; Baek D; Hwang S; Kim HJ; Park SY; Park JS; Choi GS; Kim JC; Kim JG
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1263-1267. PubMed ID: 27830320
[TBL] [Abstract][Full Text] [Related]
13. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.
Gunderson LL; Winter KA; Ajani JA; Pedersen JE; Moughan J; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett CG
J Clin Oncol; 2012 Dec; 30(35):4344-51. PubMed ID: 23150707
[TBL] [Abstract][Full Text] [Related]
14. Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal.
Oliveira SC; Moniz CM; Riechelmann R; Alex AK; Braghirolli MI; Bariani G; Nahas C; Hoff PM
J Gastrointest Cancer; 2016 Mar; 47(1):75-81. PubMed ID: 26691173
[TBL] [Abstract][Full Text] [Related]
15. Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study.
Wo JY; Plastaras JP; Metz JM; Jiang W; Yeap BY; Drapek LC; Adams J; Baglini C; Ryan DP; Murphy JE; Parikh AR; Allen JN; Clark JW; Blaszkowsky LS; DeLaney TF; Ben-Josef E; Hong TS
Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):90-95. PubMed ID: 31128146
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of survivin expression in stage III non-small cell lung cancer patients treated with platinum-based therapy.
Cho HJ; Kim HR; Park YS; Kim YH; Kim DK; Park SI
Surg Oncol; 2015 Dec; 24(4):329-34. PubMed ID: 26690822
[TBL] [Abstract][Full Text] [Related]
17. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
James RD; Glynne-Jones R; Meadows HM; Cunningham D; Myint AS; Saunders MP; Maughan T; McDonald A; Essapen S; Leslie M; Falk S; Wilson C; Gollins S; Begum R; Ledermann J; Kadalayil L; Sebag-Montefiore D
Lancet Oncol; 2013 May; 14(6):516-24. PubMed ID: 23578724
[TBL] [Abstract][Full Text] [Related]
18. Prognostic role of p53 protein expression in epidermoid carcinoma of the anal canal.
Wong CS; Tsao MS; Sharma V; Chapman WB; Pintilie M; Cummings BJ
Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):309-14. PubMed ID: 10487550
[TBL] [Abstract][Full Text] [Related]
19. Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities.
Yeung R; McConnell Y; Warkentin H; Graham D; Warkentin B; Joseph K; Doll CM
Radiat Oncol; 2015 Apr; 10():92. PubMed ID: 25903798
[TBL] [Abstract][Full Text] [Related]
20. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
